At present, Forest Labs is facing patent challenges for its hypertension treatment, Bystolic, and Savella (management of fibromyalgia). The company has filed patent infringement lawsuits against several companies looking to bring generic versions of Savella to market. The patent challengers include companies like Apotex Corp., Hetero USA Inc., Lupin Ltd., Mylan (MYL - Analyst Report), Par Pharmaceuticals, Inc., Ranbaxy Laboratories Ltd., and related companies and subsidiaries.
Read full story at http://www.zacks.com/